Bourgeois James A, Coffey Sarah M, Rivera Susan M, Hessl David, Gane Louise W, Tassone Flora, Greco Claudia, Finucane Brenda, Nelson Lawrence, Berry-Kravis Elizabeth, Grigsby Jim, Hagerman Paul J, Hagerman Randi J
Department of Psychiatry and Behavioral Sciences, University of California Davis Medical Center, Sacramento, CA 95817, USA.
J Clin Psychiatry. 2009 Jun;70(6):852-62. doi: 10.4088/JCP.08m04476. Epub 2009 May 5.
Fragile X premutation conditions are associated with a significant degree of psychopathology and thus are of interest to the psychiatrist. Remarkable advances at the molecular level have enhanced our understanding of fragile X premutation disorders.
The authors review the genetic, molecular, neuroimaging, and clinical (systemic, neurologic, and psychiatric) manifestations of the premutation carrier state (55-200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene.
The search for the psychiatric clinical manifestations of fragile X-associated conditions was accomplished by PubMed for clinical papers published between 1970 and 2008 with the following search terms: Fragile X syndrome, depression, psychosis, anxiety, and dementia.
Articles addressing psychiatric symptoms in premutation carriers based on review of the abstracts were reviewed. As the majority of the literature on this topic is based on case reports and small case series, these were included in the database.
Reported clinical manifestations of psychiatric illness in premutation carriers include an apparently significant rate of cognitive, mood, anxiety, and other psychiatric disorders. Fragile X premutation-associated conditions are part of the clinical differential diagnosis of several psychiatric syndromes, particularly in pedigrees with known fragile X syndrome cases.
Fragile X-associated psychiatric manifestations serve as a useful model for a molecular genesis of neuropsychiatric illness. Because of the multigenerational expression of fragile X-associated neuropsychiatric illness, there is a prominent role for genetic testing and genetic counseling of patients and their relatives. Genetic testing is confirmatory of the FMR1 premutation and is an essential component of the clinical evaluation. Psychopharmacologic and psychotherapeutic treatment of fragile X-associated psychiatric illnesses may improve patient function and assist in adaptation to the burden of a genetic neuropsychiatric illness.
脆性X前突变状态与显著程度的精神病理学相关,因此引起了精神科医生的关注。分子水平上的显著进展增进了我们对脆性X前突变疾病的理解。
作者综述了脆性X智力低下1(FMR1)基因前突变携带者状态(55 - 200个CGG重复序列)的遗传、分子、神经影像学和临床(全身、神经和精神)表现。
通过PubMed检索1970年至2008年间发表的临床论文,以查找脆性X相关疾病的精神科临床表现,检索词如下:脆性X综合征、抑郁、精神病、焦虑和痴呆。
基于摘要回顾,对涉及前突变携带者精神症状的文章进行了综述。由于关于该主题的大多数文献基于病例报告和小病例系列,这些都被纳入了数据库。
前突变携带者中报告的精神疾病临床表现包括认知、情绪、焦虑和其他精神障碍的明显高发率。脆性X前突变相关疾病是几种精神综合征临床鉴别诊断的一部分,特别是在有已知脆性X综合征病例的家系中。
脆性X相关的精神表现是神经精神疾病分子发病机制的有用模型。由于脆性X相关神经精神疾病的多代表达,对患者及其亲属进行基因检测和遗传咨询具有重要作用。基因检测可确认FMR1前突变,是临床评估的重要组成部分。对脆性X相关精神疾病的心理药物和心理治疗可能改善患者功能,并有助于适应遗传性神经精神疾病的负担。